Maria Papaleontiou1, Josh M Evron2, Nazanene H Esfandiari1, David Reyes-Gastelum1, Kevin C Ward3, Ann S Hamilton4, Francis Worden5, Megan R Haymart1. 1. Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. 2. Division of Endocrinology and Metabolism, Department of Internal Medicine, University of North Carolina, Chapel Hill, North Carolina. 3. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia. 4. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California. 5. Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Abstract
Background: Despite the excellent survival of most patients with differentiated thyroid cancer (DTC), recurrent and persistent disease remain major concerns for physicians and patients. However, studies on patient report of recurrent and persistent disease are lacking. Methods: Between February 1, 2017, and October 31, 2018, we surveyed eligible patients who were diagnosed with DTC between 2014 and 2015 from the Georgia and Los Angeles Surveillance, Epidemiology, and End Results cancer registries (N = 2632; response rate, 63%). Patients who reported current disease status were included in this study (n = 2454). Patient-reported data were linked to registry data. A multivariable, multinomial logistic regression analysis was conducted to determine patient and tumor characteristics associated with recurrent and persistent thyroid cancer. Quality of life was evaluated using the Patient-Reported Outcomes Measurement Information System-Global Health v1.2 questionnaire. Meaningful change in global health was defined as a minimal difference of a half standard deviation or 5 points compared with the mean (T score = 50) of a sample population matching the United States 2000 General Census. Results: Of the 2454 patients completing the survey, 95 (4.1%) reported recurrent disease and 137 (5.8%) reported persistent disease. In multinomial analyses, T3/T4 classification and cervical lymph node involvement (N1) were associated with both report of recurrent (adjusted relative risk ratio [RRR] 1.99, 95% confidence interval [CI 1.16-3.42]; adjusted RRR 2.03 [CI 1.29-3.21], respectively) and persistent disease (adjusted RRR 3.48 [CI 1.96-6.20]; adjusted RRR 3.56 [CI 2.41-5.24], respectively). Additionally, Hispanic ethnicity was associated with report of recurrent disease (adjusted RRR 1.99 [CI 1.23-3.24]). Regarding quality of life, the median scores in patients with persistent disease met criteria for meaningful change in global physical health (T-score = 44.9) and global mental health (T-score = 43.5) when compared with the general population norms. Median scores in patients with cured or recurrent disease did not meet criteria for meaningful change. Conclusions: Patient report is a reasonable method of assessing recurrent and persistent disease. Impact on quality of life is more marked for patients with reported persistent disease. Our findings will help personalize treatment and long-term follow-up in these patients.
Background: Despite the excellent survival of most patients with differentiated thyroid cancer (DTC), recurrent and persistent disease remain major concerns for physicians and patients. However, studies on patient report of recurrent and persistent disease are lacking. Methods: Between February 1, 2017, and October 31, 2018, we surveyed eligible patients who were diagnosed with DTC between 2014 and 2015 from the Georgia and Los Angeles Surveillance, Epidemiology, and End Results cancer registries (N = 2632; response rate, 63%). Patients who reported current disease status were included in this study (n = 2454). Patient-reported data were linked to registry data. A multivariable, multinomial logistic regression analysis was conducted to determine patient and tumor characteristics associated with recurrent and persistent thyroid cancer. Quality of life was evaluated using the Patient-Reported Outcomes Measurement Information System-Global Health v1.2 questionnaire. Meaningful change in global health was defined as a minimal difference of a half standard deviation or 5 points compared with the mean (T score = 50) of a sample population matching the United States 2000 General Census. Results: Of the 2454 patients completing the survey, 95 (4.1%) reported recurrent disease and 137 (5.8%) reported persistent disease. In multinomial analyses, T3/T4 classification and cervical lymph node involvement (N1) were associated with both report of recurrent (adjusted relative risk ratio [RRR] 1.99, 95% confidence interval [CI 1.16-3.42]; adjusted RRR 2.03 [CI 1.29-3.21], respectively) and persistent disease (adjusted RRR 3.48 [CI 1.96-6.20]; adjusted RRR 3.56 [CI 2.41-5.24], respectively). Additionally, Hispanic ethnicity was associated with report of recurrent disease (adjusted RRR 1.99 [CI 1.23-3.24]). Regarding quality of life, the median scores in patients with persistent disease met criteria for meaningful change in global physical health (T-score = 44.9) and global mental health (T-score = 43.5) when compared with the general population norms. Median scores in patients with cured or recurrent disease did not meet criteria for meaningful change. Conclusions: Patient report is a reasonable method of assessing recurrent and persistent disease. Impact on quality of life is more marked for patients with reported persistent disease. Our findings will help personalize treatment and long-term follow-up in these patients.
Entities:
Keywords:
persistent; population-based study; quality of life; recurrence; thyroid cancer
Authors: Sneha Goswami; Benjamin J Peipert; Michael N Mongelli; Sasha K Kurumety; Irene B Helenowski; Susan E Yount; Cord Sturgeon Journal: Surgery Date: 2019-03-18 Impact factor: 3.982
Authors: Haejin In; Karl Y Bilimoria; Andrew K Stewart; Kristen E Wroblewski; Mitchell C Posner; Mark S Talamonti; David P Winchester Journal: Ann Surg Oncol Date: 2014-02-07 Impact factor: 5.344
Authors: Bronwen E Shaw; Karen L Syrjala; Lynn E Onstad; Eric J Chow; Mary E Flowers; Heather Jim; K Scott Baker; Sarah Buckley; Diane L Fairclough; Mary M Horowitz; Stephanie J Lee Journal: Cancer Date: 2017-10-26 Impact factor: 6.860
Authors: Kevin J Kovatch; David Reyes-Gastelum; David T Hughes; Ann S Hamilton; Kevin C Ward; Megan R Haymart Journal: JAMA Otolaryngol Head Neck Surg Date: 2019-09-01 Impact factor: 6.223
Authors: Nina Jackson Levin; Anao Zhang; David Reyes-Gastelum; Debbie W Chen; Ann S Hamilton; Bradley Zebrack; Megan R Haymart Journal: J Cancer Surviv Date: 2021-10-11 Impact factor: 4.062
Authors: Kevin J Kovatch; David Reyes-Gastelum; Jennifer A Sipos; Elaine M Caoili; Ann S Hamilton; Kevin C Ward; Megan R Haymart Journal: JAMA Otolaryngol Head Neck Surg Date: 2020-12-23 Impact factor: 6.223
Authors: Maria Papaleontiou; Debbie W Chen; Mousumi Banerjee; David Reyes-Gastelum; Ann S Hamilton; Kevin C Ward; Megan R Haymart Journal: Thyroid Date: 2021-04-23 Impact factor: 6.506
Authors: Debbie W Chen; David Reyes-Gastelum; Christine M Veenstra; Ann S Hamilton; Mousumi Banerjee; Megan R Haymart Journal: Thyroid Date: 2020-09-22 Impact factor: 6.568